PT2376533T - Formulação de anticorpos - Google Patents
Formulação de anticorposInfo
- Publication number
- PT2376533T PT2376533T PT97648588T PT09764858T PT2376533T PT 2376533 T PT2376533 T PT 2376533T PT 97648588 T PT97648588 T PT 97648588T PT 09764858 T PT09764858 T PT 09764858T PT 2376533 T PT2376533 T PT 2376533T
- Authority
- PT
- Portugal
- Prior art keywords
- antibody formulation
- antibody
- formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08170884A EP2196476A1 (en) | 2008-12-10 | 2008-12-10 | Antibody formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2376533T true PT2376533T (pt) | 2016-07-13 |
Family
ID=40637230
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT97648588T PT2376533T (pt) | 2008-12-10 | 2009-12-09 | Formulação de anticorpos |
PT161626999T PT3072906T (pt) | 2008-12-10 | 2009-12-09 | Formulação de anticorpos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT161626999T PT3072906T (pt) | 2008-12-10 | 2009-12-09 | Formulação de anticorpos |
Country Status (32)
Country | Link |
---|---|
US (3) | US20110236398A1 (pt) |
EP (4) | EP2196476A1 (pt) |
JP (5) | JP6143416B2 (pt) |
KR (2) | KR20170044211A (pt) |
CN (3) | CN102245639B (pt) |
AU (1) | AU2009324371B2 (pt) |
BR (1) | BRPI0922730A2 (pt) |
CA (1) | CA2745938C (pt) |
CL (1) | CL2011001406A1 (pt) |
CO (1) | CO6361952A2 (pt) |
CY (2) | CY1117735T1 (pt) |
DK (2) | DK2376533T3 (pt) |
EC (1) | ECSP11011192A (pt) |
ES (2) | ES2579835T3 (pt) |
HK (1) | HK1159130A1 (pt) |
HR (2) | HRP20211899T1 (pt) |
HU (2) | HUE028408T2 (pt) |
IL (3) | IL264316B2 (pt) |
LT (1) | LT3072906T (pt) |
MA (1) | MA33023B1 (pt) |
MX (1) | MX2011006242A (pt) |
MY (2) | MY166050A (pt) |
NZ (1) | NZ592918A (pt) |
PE (1) | PE20120342A1 (pt) |
PL (2) | PL3072906T3 (pt) |
PT (2) | PT2376533T (pt) |
RU (2) | RU2745601C2 (pt) |
SI (2) | SI2376533T1 (pt) |
SM (1) | SMT201600222B (pt) |
TN (1) | TN2011000229A1 (pt) |
WO (1) | WO2010066762A1 (pt) |
ZA (1) | ZA201103362B (pt) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
KR20120130757A (ko) | 2010-02-26 | 2012-12-03 | 노보 노르디스크 에이/에스 | 안정한 항체 함유 조성물 |
CA2976671C (en) | 2010-03-01 | 2021-01-12 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
CA2800188A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
AR082319A1 (es) * | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CN103282042B (zh) | 2010-09-17 | 2014-12-10 | 巴克斯特国际公司 | 通过具有组氨酸的水性制剂在弱酸性至中性pH稳定的免疫球蛋白 |
CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
TWI700093B (zh) | 2011-03-16 | 2020-08-01 | 法商賽諾菲公司 | 雙重v區類抗體蛋白質之用途 |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
ES2911677T3 (es) | 2011-10-03 | 2022-05-20 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos |
FI123630B (fi) | 2011-10-24 | 2013-08-30 | Teknologian Tutkimuskeskus Vtt | Menetelmä NFC-kalvojen valmistamiseksi alustoille |
WO2013082282A1 (en) | 2011-12-02 | 2013-06-06 | lNOVARTIS AG | Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease. |
DE12858350T1 (de) | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | Modifizierte mrna zusammensetzungen |
MX370199B (es) * | 2012-02-16 | 2019-12-05 | Santarus Inc | Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a). |
KR102459666B1 (ko) * | 2012-03-16 | 2022-10-27 | 리제너론 파마슈티칼스 인코포레이티드 | pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물 |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
EP3501550A1 (en) | 2012-04-02 | 2019-06-26 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
UA115789C2 (uk) * | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
IN2015KN00657A (pt) * | 2012-09-20 | 2015-07-17 | Morphosys Ag | |
WO2014078502A1 (en) * | 2012-11-16 | 2014-05-22 | Novartis Ag | Use of il-1 beta binding antibodies for treating peripheral arterial disease |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
JP2016515515A (ja) * | 2013-03-15 | 2016-05-30 | バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC | 抗プロラクチン受容体抗体製剤 |
TWI679019B (zh) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗il-4/抗il-13之雙特異性抗體調配物 |
NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
JP6707469B2 (ja) * | 2014-05-28 | 2020-06-10 | ノノ インコーポレイテッド | アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤 |
RU2017107847A (ru) * | 2014-09-03 | 2018-10-03 | Медиммун Лимитед | Стабильный состав на основе антитела к il-4r-альфа |
JP2017537084A (ja) | 2014-11-12 | 2017-12-14 | トラコン ファーマシューティカルズ、インコーポレイテッド | 抗エンドグリン抗体及びその用途 |
US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
AR104847A1 (es) | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
ES2823279T3 (es) | 2015-12-07 | 2021-05-06 | Merck Patent Gmbh | Formulación farmacéutica acuosa que comprende el anticuerpo anti-PD-1 Avelumab |
EP3487584A1 (en) * | 2016-07-21 | 2019-05-29 | Novartis AG | Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis |
US10961314B2 (en) * | 2016-09-27 | 2021-03-30 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition comprising an anti-IL-6 receptor antibody |
BR112019010064A2 (pt) | 2016-11-18 | 2019-10-01 | Astellas Pharma Inc | novo fragmento fab do anticorpo muc1 anti-humano |
TW201904993A (zh) * | 2017-06-22 | 2019-02-01 | 瑞士商諾華公司 | IL-1β 結合抗體之用途 |
TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類CEACAM5抗體Fab片段 |
CN111315412A (zh) * | 2017-09-13 | 2020-06-19 | 诺华股份有限公司 | Il-1b结合抗体用于治疗酒精性肝炎的用途 |
KR20210074284A (ko) | 2018-10-10 | 2021-06-21 | 아스텔라스세이야쿠 가부시키가이샤 | 표지부-항인간 항체 Fab 프래그먼트 복합체를 포함하는 의약 조성물 |
MA55033A (fr) * | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业(上海)股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
US20240052026A1 (en) * | 2020-12-22 | 2024-02-15 | Bio-Thera Solutions, Ltd. | Stable antibody formulation, preparation method therefor, and applications thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
CN102416176A (zh) | 1995-07-27 | 2012-04-18 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白质制剂 |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
TWI302149B (en) | 1999-09-22 | 2008-10-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
PE20020132A1 (es) | 2000-06-29 | 2002-03-04 | Abbott Lab | Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos |
EP1336410A4 (en) * | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | PROTEIN INJECTION PREPARATIONS |
GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
JP5290489B2 (ja) * | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Igg抗体の安定な液体医薬製剤 |
US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
CN1798575A (zh) * | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
TW200638943A (en) * | 2005-01-28 | 2006-11-16 | Wyeth Corp | Stabilized liquid polypeptide formulations |
GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
EP1871806A2 (en) * | 2005-03-08 | 2008-01-02 | Pharmacia & Upjohn Company LLC | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
JP5053264B2 (ja) * | 2005-05-19 | 2012-10-17 | アムジェン インコーポレイテッド | 抗体の安定性を増加させるための組成物および方法 |
PT1940465E (pt) | 2005-10-26 | 2012-10-03 | Novartis Ag | Nova utilização para compostos de il-1 beta |
CN201044845Y (zh) * | 2006-10-28 | 2008-04-09 | 李开元 | 自动注射器 |
EP2094729A1 (en) * | 2006-12-11 | 2009-09-02 | F.Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
CA2681743A1 (en) * | 2007-03-22 | 2008-09-25 | Imclone Llc | Stable antibody formulations |
EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
-
2008
- 2008-12-10 EP EP08170884A patent/EP2196476A1/en not_active Ceased
-
2009
- 2009-12-09 EP EP16162699.9A patent/EP3072906B1/en active Active
- 2009-12-09 PE PE2011001179A patent/PE20120342A1/es active IP Right Grant
- 2009-12-09 ES ES09764858.8T patent/ES2579835T3/es active Active
- 2009-12-09 NZ NZ592918A patent/NZ592918A/xx unknown
- 2009-12-09 RU RU2015132431A patent/RU2745601C2/ru not_active Application Discontinuation
- 2009-12-09 HU HUE09764858A patent/HUE028408T2/en unknown
- 2009-12-09 DK DK09764858.8T patent/DK2376533T3/en active
- 2009-12-09 KR KR1020177009939A patent/KR20170044211A/ko not_active Application Discontinuation
- 2009-12-09 SI SI200931459A patent/SI2376533T1/sl unknown
- 2009-12-09 SI SI200932153T patent/SI3072906T1/sl unknown
- 2009-12-09 MX MX2011006242A patent/MX2011006242A/es active IP Right Grant
- 2009-12-09 CN CN200980149644.4A patent/CN102245639B/zh active Active
- 2009-12-09 EP EP20197506.7A patent/EP3792282A1/en active Pending
- 2009-12-09 LT LTEP16162699.9T patent/LT3072906T/lt unknown
- 2009-12-09 HR HRP20211899TT patent/HRP20211899T1/hr unknown
- 2009-12-09 PT PT97648588T patent/PT2376533T/pt unknown
- 2009-12-09 PL PL16162699T patent/PL3072906T3/pl unknown
- 2009-12-09 AU AU2009324371A patent/AU2009324371B2/en active Active
- 2009-12-09 BR BRPI0922730A patent/BRPI0922730A2/pt not_active Application Discontinuation
- 2009-12-09 KR KR1020117015821A patent/KR101762966B1/ko active IP Right Grant
- 2009-12-09 JP JP2011540063A patent/JP6143416B2/ja active Active
- 2009-12-09 IL IL264316A patent/IL264316B2/en unknown
- 2009-12-09 CN CN201410730219.7A patent/CN104399076B/zh active Active
- 2009-12-09 EP EP09764858.8A patent/EP2376533B1/en active Active
- 2009-12-09 MY MYPI2014002791A patent/MY166050A/en unknown
- 2009-12-09 RU RU2011127913/15A patent/RU2563179C2/ru active
- 2009-12-09 DK DK16162699.9T patent/DK3072906T3/da active
- 2009-12-09 CA CA2745938A patent/CA2745938C/en active Active
- 2009-12-09 US US13/133,843 patent/US20110236398A1/en not_active Abandoned
- 2009-12-09 MY MYPI2011002067A patent/MY157772A/en unknown
- 2009-12-09 CN CN202111066425.9A patent/CN114225022A/zh active Pending
- 2009-12-09 PT PT161626999T patent/PT3072906T/pt unknown
- 2009-12-09 PL PL09764858.8T patent/PL2376533T3/pl unknown
- 2009-12-09 ES ES16162699T patent/ES2900624T3/es active Active
- 2009-12-09 HU HUE16162699A patent/HUE056626T2/hu unknown
- 2009-12-09 WO PCT/EP2009/066675 patent/WO2010066762A1/en active Application Filing
- 2009-12-09 MA MA33984A patent/MA33023B1/fr unknown
-
2011
- 2011-05-09 ZA ZA2011/03362A patent/ZA201103362B/en unknown
- 2011-05-10 TN TN2011000229A patent/TN2011000229A1/fr unknown
- 2011-05-16 IL IL212922A patent/IL212922B/en active IP Right Grant
- 2011-06-09 CL CL2011001406A patent/CL2011001406A1/es unknown
- 2011-06-10 CO CO11072271A patent/CO6361952A2/es not_active Application Discontinuation
- 2011-07-08 EC EC2011011192A patent/ECSP11011192A/es unknown
- 2011-12-20 HK HK11113720.7A patent/HK1159130A1/zh unknown
-
2012
- 2012-08-15 US US13/586,185 patent/US8623367B2/en active Active
-
2015
- 2015-07-01 JP JP2015132999A patent/JP2015231997A/ja not_active Withdrawn
-
2016
- 2016-06-27 HR HRP20160754TT patent/HRP20160754T1/hr unknown
- 2016-06-30 CY CY20161100603T patent/CY1117735T1/el unknown
- 2016-07-11 SM SM201600222T patent/SMT201600222B/it unknown
-
2018
- 2018-05-29 JP JP2018102715A patent/JP2018168158A/ja not_active Withdrawn
-
2020
- 2020-07-16 US US16/930,475 patent/US20200384108A1/en active Pending
- 2020-08-06 JP JP2020133477A patent/JP7286595B2/ja active Active
- 2020-08-10 IL IL276622A patent/IL276622A/en unknown
-
2021
- 2021-12-07 CY CY20211101069T patent/CY1124844T1/el unknown
-
2023
- 2023-05-24 JP JP2023085464A patent/JP2023109938A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276622A (en) | Antibody formulation | |
HK1214947A1 (zh) | 抗體製劑 | |
HRP20171011T8 (hr) | ANTI-cMET ANTITIJELO | |
EP2358392A4 (en) | ANTIBODY FORMULATION | |
EP2077859A4 (en) | ANTIBODY FORMULATION | |
ZA201204266B (en) | Antibody formulation | |
ZA201106503B (en) | Antibody formulation | |
ZA201203242B (en) | Antibody formulation | |
EP3064512C0 (en) | ANTIBODIES AGAINST CLDN6 | |
ZA201101343B (en) | Novel antibody formulation | |
ZA201102119B (en) | Improved antibody libraies | |
GB0822633D0 (en) | Formulation | |
ZA201004772B (en) | Novel formulation | |
GB0814376D0 (en) | Formulation | |
GB0911770D0 (en) | Antibody | |
GB0817622D0 (en) | Antibody | |
GB0817621D0 (en) | Antibody | |
GB0806445D0 (en) | Formulation | |
GB0817663D0 (en) | Formulation | |
GB0819113D0 (en) | An antibody |